Literature DB >> 3612556

Opioid activities of D-Arg2-substituted tetrapeptides.

T Sato, S Sakurada, T Sakurada, S Furuta, K Chaki, K Kisara, Y Sasaki, K Suzuki.   

Abstract

The antinociceptive effects and mechanisms of action of H-Tyr-D-Ala-Phe-Gly-OH, H-Tyr-D-Arg-Phe-Gly-OH and H-Tyr-D-Arg-Phe-sarcosine(Sar)-OH have been investigated. The ED50 values of these peptides were 510.0, 8.2 and 2.0 pmol, respectively, when administered i.c.v. in the mouse tail-pressure test (dermorphin = 5.7 pmol and morphine = 1.2 nmol). These activities were remarkably potent and relatively long lasting. Their IC50 values were 676.8, 23.1 and 6.6 nM, respectively (dermorphin = 3.75 and morphine = 214.3 nM) in the guinea pig isolated ileum assay, and 138.50, 5.25 and 1.10 nM, respectively (dermorphin = 3.80 and morphine = 28.00 nM) in the radioreceptor assay utilizing [3H]naloxone as the opioid receptor ligand. In the evaluation of their inhibitory effects to enkephalin-degrading enzymes, the IC50 values of H-Tyr-D-Arg-Phe-Gly-OH, H-Tyr-D-Arg-Phe-Sar-OH and H-Tyr-D-Ala-Phe-Gly-OH were 5.4, 14.5 and more than 50.0 microM, respectively (bestatin = 0.1 microM) against aminopeptidase and 1.18, 1.40 and more than 50.0 microM, respectively (captopril = 0.38 and D-Phe-2S-, 3R-3-amino-2-hydroxy-4-phenylbutanoic acid = more than 100 microM) against the cleaving enzymes of enkephalin at its Gly3-Phe4 bond. The authors suggest that the marked antinociceptive potency of H-Tyr-D-Arg-Phe-Gly-OH and H-Tyr-D-Arg-Phe-Sar-OH is mainly due to high opioid receptor affinity. Their inhibitory effects on enkephalin-degrading enzymes and enzymatic stability also greatly contribute to their potent and long-lasting opioid activities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612556

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Preparation and evaluation at the delta opioid receptor of a series of linear leu-enkephalin analogues obtained by systematic replacement of the amides.

Authors:  Kristina Rochon; Arnaud Proteau-Gagné; Philippe Bourassa; Jean-François Nadon; Jérome Côté; Véronique Bournival; Fernand Gobeil; Brigitte Guérin; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

2.  Antinociception and physical dependence produced by [D-Arg2] dermorphin tetrapeptide analogues and morphine in rats.

Authors:  K Chaki; S Kawamura; K Kisara; S Sakurada; T Sakurada; Y Sasaki; T Sato; K Susuki
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

3.  Production of antinociception by peripheral administration of [Lys7]dermorphin, a naturally occurring peptide with high affinity for mu-opioid receptors.

Authors:  L Negri; R Lattanzi; P Melchiorri
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

4.  Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.

Authors:  Alaa Talhami; Avi Swed; Shmuel Hess; Oded Ovadia; Sarit Greenberg; Adi Schumacher-Klinger; David Rosenthal; Deborah E Shalev; Mattan Hurevich; Philip Lazarovici; Amnon Hoffman; Chaim Gilon
Journal:  Front Chem       Date:  2020-11-12       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.